Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Democrats Running Out Of Time On Drug Pricing Reform

Executive Summary

Is less ambitious drug pricing reform better than nothing? Senate Finance Committee Chair Wyden still pushing for a version of the most aggressive policy, direct government price negotiation.  

You may also be interested in...



No More Humiras: Thinking Through The Impact Of Price Negotiation In US

The final push by Democrats to enact a drug price ‘negotiation’ bill is under way. The prospects are uncertain, but the intended impact is not: never again will there be a brand as successful for as long as Humira.

Drug Pricing Takes Over User Fee Hearing – And That Might Be Good News For Industry

Innovator companies are not generally happy when congressional committees focus on the cost of prescription drugs, particularly in hearings supposedly focused on other subjects. But when a Senate committee discussing the US FDA user fee reauthorization process devotes considerable time to the theme of pricing, it probably isn’t such a bad thing.

US Rx Spending Growth Projected To Stay Modest; Will Political Debate Change?

The latest update by the US Centers for Medicare & Medicaid Services to national health care spending forecasts continues to put prescription drugs in line with – or even slightly below – overall growth rates. Of course, that likely won’t change the political attention to the issue in 2022.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel